Skip to main content
OpenTrials
Completed

NCT Number: NCT04563039

Acoustic Enhancer Research on Laser Lithotripsy (AEROLITH)

A pivotal study to evaluate the safety and effectiveness of Applaud Acoustic Enhancer when used in conjunction with conventional ureteroscopic laser lithotripsy (URS-LL) in the treatment of subjects with urinary stones.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Alabama, Birmingham, Alabama, United States

Loading trial locations.

About this study

The AEROLITH Clinical Study will evaluate the safety and effectiveness of Applaud Acoustic Enhancer when used in conjunction with conventional ureteroscopic laser lithotripsy (URS-LL) in the treatment of subjects with urinary stones. The clinical study is a prospective, multi-center, two-arm, randomized, double blinded study.

A total of 196 subjects will be enrolled in this study at up to 27 investigational sites located in the U.S.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female aged ≥ 18 years to ≤ 75 years
  • Provides written informed consent
  • Patients with at least one urinary stone measuring 6mm or greater (but no more than a cumulative diameter of 20mm) located proximally to the iliac vessels on one side may be treated.
  • Urinary stone(s) should be apparent on a CT scan within 60 days prior to study enrollment. Stone assessment will be conducted using CT imaging following CLIN-0025: AEROLITH IDE Study Screening Guide.
  • Patients with bilateral stones are allowed but only one side may be treated. Only the treated side will be evaluated for safety and effectiveness
  • Patients may enter the study with a stent in place.
  • Patients presenting with absence of a Urinary Tract Infection as confirmed using urinalysis

Exclusion criteria

  • Patients with stones exceeding a cumulative diameter of 20mm on the side to be treated. Note: Punctate stones measuring ≤ 2mm do not count in the cumulative diameter limit.
  • Patients with ureteral stones located distal to the iliac vessels on the side to be treated
  • Diagnosis of radiolucent stones (on the side to be treated) on KUB or Scout CT Imaging
  • For patients who have a ureteral stent in place, patient is excluded if stent is calcified or encrusted as verified using standard of care imaging (e.g. KUB X-ray)
  • Patients who have had prior URS-LL within 3 months on the side to be treated at the time of consent.
  • History of cystinuria
  • Urine pH is < 5.5.
  • Patients with known history of recurrent uric acid stones
  • Untreated urinary tract infection (UTI)
  • History of drug-resistant chronic UTI
  • If female, pregnant as confirmed using urine test to be conducted on the day of the procedure.
  • Patient has an American Society of Anesthesiologists (ASA) physical classification level of 4 or greater.
  • Known sensitivity to possible medications used before, during, or after the URS Laser Lithotripsy procedure, including but not limited to the following: sedative agents, general anesthetics, topical anesthetics, and opioid analgesics
  • Stones suspected in calyceal diverticula
  • Horseshoe kidney
  • Congenitally ectopic pelvic kidneys
  • Full staghorn calculi >2cm
  • Patients with elevated serum creatinine > 1.5mg/dl
  • Patients with a solitary kidney
  • Malrotated kidney on the side with urinary stone
  • Duplicated collecting system or duplicated ureters
  • Patients who are currently involved in any investigational drug or device trial or have been enrolled in such trials within 30 days of index procedure
  • Patients who are actively taking antiplatelet and anti-coagulation except low dose aspirin
  • Prostate biopsy within the last 3 months
  • History of radiation therapy of abdomen and pelvis
  • History of urinary tract reconstruction
  • Other factors that the investigator feels would interfere with the participation and completion of the study such as:
  • Inability to provide voluntary consent
  • Inability to understand the clinical investigation or cooperate with investigational procedures
  • Planned relocation or unable to return for required follow-up visits
  • Vulnerable individuals (mentally disabled, physically disabled, prisoner, etc.)

Treatment and study plan

Ureteroscopy Laser Lithotripsy (URS-LL) with Acoustic Enhancer

Device

Applaud's Acoustic Enhancer is provided in a lyophilized form. After reconstitution, it is a liquid, containing micron-scale particles that are made of a perfluoroalkane gas core with a lipid shell. The device is intended to be used with cleared/approved pulsed laser systems in fragmenting urinary stones (calculi) in the upper (superior) pole, lower (inferior) pole, and interpolar region of the kidney, pelvis of the kidney, and proximal ureter.

Standard Ureteroscopic Laser Lithotripsy

Device

Standard of care Ureteroscopic Laser Lithotripsy

Primary outcomes

  1. Number of Participants With Absence of or Have Residual Fragments Measuring Less </= to 2 mm

    Time frame: At 30 days post index procedure

    Study subjects who present with a complete absence of stones, or have residual fragments measuring less than or equal to 2 mm on the treatment side, as assessed by CT imaging

Sponsors and collaborators

Lead sponsor

Avvio Medical

Industry

Registry information

Official study title

Evaluation of Applaud Medical's Acoustic Enhancer With Laser Lithotripsy System in the Treatment of Urinary Stones

Acronym: AEROLITH

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
Sep 24, 2020
Registry last updated
Apr 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.